Document is current

Any future updates will be listed below

Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Crossref DOI link: https://doi.org/10.1007/s13555-026-01876-x

Published Online: 2026-08-28

Published Print: 2026-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark